EFFICACY AND SAFETY OF ANTI-TNFα HUMAN MONOCLONAL ANTIBODIES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS AND SECONDARY RESISTANCE TO OTHER GENETICALLY ENGINEERED BIOLOGICAL AGENTS
Treatment of juvenile idiopathic arthritis (JIA) is one of the most important challenges in paediatric rheumatology. The results of the retrospective observational study of adalimumab (anti TNF human monoclonal antibodies) efficacy and safety in real clinical practice in treatment of 56 patients wit...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
"Paediatrician" Publishers LLC
2012-07-01
|
| Series: | Вопросы современной педиатрии |
| Subjects: | |
| Online Access: | https://vsp.spr-journal.ru/jour/article/view/458 |
| Summary: | Treatment of juvenile idiopathic arthritis (JIA) is one of the most important challenges in paediatric rheumatology. The results of the retrospective observational study of adalimumab (anti TNF human monoclonal antibodies) efficacy and safety in real clinical practice in treatment of 56 patients with JIA and primary or secondary resistance to other genetically engineered biological agents (48 — infiximab, 2 — etanercept, 5 — rituximab, 1 — abatacept) are demonstrated in this article. Adalimumab was administered hypodermically at the dosage of 40 mg per 2 weeks. The efficacy was assessed according to the criteria of ACR (pediatric). In 4 weeks of treatment in 100% of patients the 30% improvement was established, in 80% of patients — 50% improvement, and in 60% of patients — 70% improvement. In 25 weeks of treatment 30% improvement was documented in 100% of patients (56), 50% improvement — in 91% (51), 70% improvement — in 74% (41). Inactive stage of the disease was established in 24 weeks in 55% of children; in 1 year — in 85%; remission was established in 55% of children. No severe side effects were found. Therefore, the received data show that adalimumab is effective in patients with JIA, both with primary and secondary resistance to other biological agents. |
|---|---|
| ISSN: | 1682-5527 1682-5535 |